Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.
